Over 40% of COVID-19 vaccines are in the first phase of clinical trials

Is COVID-19 vaccinated at the end of the year at the earliest? Over 40% are still in the first phase of clinical trials.

According to the statistics of the World Health Organization, as of November 12th, al menos 48 candidate vaccines for COVID-19 pneumonia have entered clinical trials worldwide. Entre ellos, the first stage is the most, accounting for 43.75%. Entre el 11 vaccines that have entered the third phase, the most are from China, accounting for 36.36%. Zhang Wenhong, director of the Department of Infectious Diseases of Huashan Hospital affiliated to Fudan University in Shanghai, said in an exclusive interview that it is expected that vaccination will basically start around the world at the end of this year or early next year.

According to the ordering situation, the vaccines jointly developed by Pfizer of the United States, biontech of Germany and Fosun of China have reached a purchase agreement with the European Union (up to 300 million doses). Moderna has signed 5 million doses of vaccines with Britain, and the first batch is expected to be delivered next spring. According to Russian President Vladimir Putin, dozens of countries have expressed their wish to buy Russian COVID-19 vaccine, and Russia is willing to cooperate. In the United States, the freezer for storing COVID-19 vaccine is in short supply.

In terms of pricing, according to Pfizer, the company reached an agreement with the US government in July: to provide 100 million potential vaccines to the US government at the price of US$ 39 for two doses or US$ 19.5 for each dose, which is only applicable to the United States.